Exforge^® (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact

Review

(2943) Views  (1729) Full article downloads

Authors: Jean-Marie Krzesinski, Eric P Cohen

Published Date June 2009 Volume 2009:4 Pages 1 - 11

DOI: http://dx.doi.org/10.2147/CE.S6007

Jean-Marie Krzesinski¹, Eric P Cohen²

¹Division of Nephrology/Transplantation, University of Liège – Sart Tilman, Belgium; ²Nephrology Division, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

Introduction: Hypertension is an important risk factor for cardiovascular disease and its management requires improvement. New treatment strategies are needed.

Aims: This review analyses one of these strategies, which is the development of effective and safe combination therapy. Indeed, at least two antihypertensive agents are often needed to achieve blood pressure control. Exforge^® (Novartis) is a new drug combination of the calcium channel blocker, amlodipine, and the angiotensin II receptor blocker, valsartan.

Evidence review: The amlodipine/valsartan combination is an association of two well-known antihypertensive products with specific targets in cardiovascular protection, namely calcium channel blockade and antagonism of the renin-angiotensin-aldosterone system. This kind of association, with neutral metabolic properties and significant antihypertensive efficacy, could be a useful new antihypertensive product. Currently available data have shown that this new combination is well-tolerated and effective even in severe hypertension.

Clinical value: Clinical trials are ongoing for further assessment of the efficacy, compliance, and safety of this combination and its congeners. No data exist to prove that the amlodipine/valsartan combination is better than other antihypertensive strategies for cardiovascular or renal protection, but some trials with other combination therapies show such potential advantage.

Keywords: arterial hypertension, treatment, combination therapy, calcium channel blocker, amlodipine, angiotensin II receptor blocker, valsartan

Other articles by Professor Jean-Marie Krzesinski